JOUD HAJJAR to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications JOUD HAJJAR has written about Antibodies, Monoclonal, Humanized.
Connection Strength
0.385
-
Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers. J Immunother Cancer. 2021 04; 9(4).
Score: 0.134
-
Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors. J Immunother Cancer. 2020 04; 8(1).
Score: 0.125
-
Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 03; 8(1).
Score: 0.125